{"id":16571,"date":"2022-12-02T11:46:01","date_gmt":"2022-12-02T11:46:01","guid":{"rendered":"https:\/\/dailytalks.org\/?p=16571"},"modified":"2022-12-02T11:46:01","modified_gmt":"2022-12-02T11:46:01","slug":"abivax-releases-the-results-of-its-november-9-2022-ad-hoc-ordinary-and-extraordinary-general-meeting","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=16571","title":{"rendered":"Abivax Releases the Results of its November 9, 2022 Ad Hoc Ordinary and Extraordinary General Meeting"},"content":{"rendered":"<p>Shareholders approved all proposed resolutionsPARIS, FRANCE \/ ACCESSWIRE \/ November 15, 2022 \/ Abivax SA (Euronext Paris: FR0012333284 &#8211; ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, held an ad hoc ordinary and extraordinary general meeting of shareholders on November 9&#8230;<br \/><a href=\"https:\/\/www.accesswire.com\/viewarticle.aspx?id=726016&#038;lang=en\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shareholders approved all proposed resolutionsPARIS, FRANCE \/ ACCESSWIRE \/ November 15, 2022 \/ Abivax SA<\/p>\n","protected":false},"author":1,"featured_media":16572,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[],"class_list":["post-16571","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tech"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/16571-abivax-releases-the-results-of-its-november-9-2022-ad-hoc-ordinary-and-extraordinary-general-meeting.gif",189,106,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/16571-abivax-releases-the-results-of-its-november-9-2022-ad-hoc-ordinary-and-extraordinary-general-meeting-150x106.gif",150,106,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/16571-abivax-releases-the-results-of-its-november-9-2022-ad-hoc-ordinary-and-extraordinary-general-meeting.gif",189,106,false],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/16571-abivax-releases-the-results-of-its-november-9-2022-ad-hoc-ordinary-and-extraordinary-general-meeting.gif",189,106,false],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/16571-abivax-releases-the-results-of-its-november-9-2022-ad-hoc-ordinary-and-extraordinary-general-meeting.gif",189,106,false],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/16571-abivax-releases-the-results-of-its-november-9-2022-ad-hoc-ordinary-and-extraordinary-general-meeting.gif",189,106,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/16571-abivax-releases-the-results-of-its-november-9-2022-ad-hoc-ordinary-and-extraordinary-general-meeting.gif",189,106,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/16571-abivax-releases-the-results-of-its-november-9-2022-ad-hoc-ordinary-and-extraordinary-general-meeting.gif",189,106,false],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/16571-abivax-releases-the-results-of-its-november-9-2022-ad-hoc-ordinary-and-extraordinary-general-meeting.gif",189,106,false],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/12\/16571-abivax-releases-the-results-of-its-november-9-2022-ad-hoc-ordinary-and-extraordinary-general-meeting.gif",189,106,false]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=35\" rel=\"category\">Tech<\/a>","tag_info":"Tech","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/16571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16571"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/16571\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/16572"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}